Webbläsaren som du använder stöds inte av denna webbplats. Alla versioner av Internet Explorer stöds inte längre, av oss eller Microsoft (läs mer här: * https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Var god och använd en modern webbläsare för att ta del av denna webbplats, som t.ex. nyaste versioner av Edge, Chrome, Firefox eller Safari osv.

Systemic administration of Neuregulin-1ß(1) protects dopaminergic neurons in a mouse model of Parkinson's disease.

In English

Författare

  • Thomas Carlsson
  • Friederike R Schindler
  • Matthias Höllerhage
  • Candan Depboylu
  • Oscar Arias-Carrión
  • Stefan Schnurrbusch
  • Thomas W Rösler
  • Wojciech Wozny
  • Gerhard P Schwall
  • Karlfried Groebe
  • Wolfgang H Oertel
  • Patrik Brundin
  • André Schrattenholz
  • Günter U Höglinger
Visa allt

Summary, in English

Neuregulin-1 (Nrg1) is genetically linked to schizophrenia, a disease caused by neurodevelopmental imbalance in dopaminergic function. The Nrg1 receptor ErbB4 is abundantly expressed on midbrain dopaminergic neurons. Nrg1 has been shown to penetrate blood-brain barrier, and peripherally administered Nrg1 activates ErbB4 and leads to a persistent hyperdopaminergic state in neonatal mice. These data prompted us to study the effect of peripheral administration of Nrg1 in the context of Parkinson's disease, a neurodegenerative disorder affecting the dopaminergic system in the adult brain. We observed that systemic injections of the extracellular domain of Nrg1ß(1) (Nrg1ß(1) -ECD) increased dopamine levels in the substantia nigra and striatum of adult mice. Nrg1ß(1) -ECD injections also significantly protected the mouse nigrostriatal dopaminergic system morphologically and functionally against 6-hydroxydopamine-induced toxicity in vivo. Moreover, Nrg1ß(1) -ECD also protected human dopaminergic neurons in vitro against 6-hydroxydopamine. In conclusion, we have identified Nrg1ß(1) -ECD as a neurotrophic factor for adult mouse and human midbrain dopaminergic neurons with peripheral administratability, warranting further investigation as therapeutic option for PD patients.

Publiceringsår

2011

Språk

Engelska

Sidor

1066-1074

Publikation/Tidskrift/Serie

Journal of Neurochemistry

Volym

117

Issue

6

Dokumenttyp

Artikel i tidskrift

Förlag

Wiley-Blackwell

Ämne

  • Neurosciences

Nyckelord

  • ErbB4 receptor
  • dopamine
  • neuregulin
  • neuroprotection
  • Parkinson's
  • disease

Status

Published

ISBN/ISSN/Övrigt

  • ISSN: 1471-4159